The aim of this study was to assess in healthy subjects the safety , tolerability , pharmacokinetics , and pharmacodynamics of ponesimod , an oral selective sphingosine-1-phosphate receptor 1 ( S1P1 ) modulator in development for multiple sclerosis , by using an uptitration scheme up to supratherapeutic doses .